Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Colorectal Cancer Treatments and Studies, Gastric Cancer Management and Outcomes, Lung Cancer Treatments and Mutations, and Cancer Genomics and Diagnostics.
Nivolumab plus ipilimumab (N+I) in patients (pts) with pancreatic cancer (PC) with <i>BRCA1/2</i> mutation (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study
A Phase II Study Investigating Cabozantinib in Patients with Refractory Metastatic Colorectal Cancer (AGICC 17CRC01)
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer